<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375101</url>
  </required_header>
  <id_info>
    <org_study_id>88705</org_study_id>
    <nct_id>NCT01375101</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      Lichen planus (LP) is a common chronic inflammatory mucocutaneous disease with an immunologic
      etiology ,which has number of different clinical forms. Alternative natural or herbal origine
      drugs with antioxidant and anti-inflammatory properties have been used individually or in
      combination with systemic corticosteroids in order to decrease adverse drug reactions.

      This study was conducted to evaluate the effect of quercetin on treatment of erosive
      -atrophic lesions of oral lichen planus (OLP).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effects of this Drug on OLP measured with VAS scale for pain and evaluation of intensity of lesions.</measure>
    <time_frame>2 months</time_frame>
    <description>In the present work the Analogical Visual Scale is used TO evaluate pain,and we also record the intensity of lesions weekly and any side effect of this Drug</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atrophic Oral Lichen Planus</condition>
  <condition>Erosive Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>quercetin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsul is produced with lactose for using in placebo/ control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The patient is directed to use placebo capsule two times a day, ,until the one mouth</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quercetin</intervention_name>
    <description>The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth</description>
    <arm_group_label>quercetin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmation of clinical diagnosis of Atrophic and erosive lichen planus by
             histological examination

          -  two weeks wash out periods after the last treatment

          -  having the experience of atrophic and erosive lesion greater than 1 cm having the
             experience of pain and burning greater than 3.5 in VAS Score

        Exclusion Criteria:

          -  confirmation of dysplasia and malignancy in histologic examination

          -  confirmation of lichenoid reaction in histologic examination

          -  pregnancy and breast feeding

          -  using fluorokinolon and cyclosporin which interact with quercetin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>maryam amirchaghmaghi, assistant professor</last_name>
    <phone>0098-0511889201</phone>
    <email>amirchakhmaghim@mums.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mashhad university of Medical science, Research Center of oral and maxillofacial medicine</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan Razavi</state>
        <zip>91735</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>maryam amirchaghmaghi, assistant professor</last_name>
      <phone>0098-0511882901</phone>
      <email>amirchakhmaghim@mums.ac.ir</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>July 25, 2011</last_update_submitted>
  <last_update_submitted_qc>July 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>maryam amirchaghmaghi</name_title>
    <organization>assistant professor of oral medicine department- mashhad medical school</organization>
  </responsible_party>
  <keyword>lichen planus</keyword>
  <keyword>quercetin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
    <mesh_term>Lichen Planus, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

